News
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase III IMforte study of Tecentriq® (atezolizumab) in combination with lurbinectedin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback